GastrointestinalResearch Phase

Guanylin

Endogenous peptide

Overview

Guanylin is a 15-amino acid endogenous peptide hormone that activates guanylate cyclase-C (GC-C) receptors on intestinal epithelial cells. Upon binding, it stimulates intracellular cyclic GMP production, which regulates chloride and bicarbonate secretion into the intestinal lumen and promotes fluid secretion.

Mechanism of Action

This mechanism enhances intestinal motility and fluid balance. Guanylin functions as a paracrine regulator of intestinal homeostasis and salt-water equilibrium..

Research Summary & Key Findings

Guanylin itself has been characterized primarily in preclinical studies elucidating its role in intestinal fluid regulation and epithelial cell function. Synthetic analogs of guanylin, such as linaclotide and plecanatide, have been developed and approved for clinical use in chronic constipation and irritable bowel syndrome with constipation. Native guanylin remains a research tool rather than a therapeutic agent.

Clinical Status

Research Phase

Guanylin is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.

Administration Routes

Endogenous peptide

Related Peptides in Gastrointestinal

Find a Provider

Find a verified provider who offers Guanylin therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Guanylin.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.